Wendell David Associates Inc. Has $1.39 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Wendell David Associates Inc. decreased its position in Edwards Lifesciences Co. (NYSE:EW) by 20.6% in the 4th quarter, HoldingsChannel reports. The fund owned 18,795 shares of the medical research company’s stock after selling 4,880 shares during the period. Wendell David Associates Inc.’s holdings in Edwards Lifesciences were worth $1,391,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Bowman & Co S.C. raised its position in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after purchasing an additional 148 shares in the last quarter. JFS Wealth Advisors LLC raised its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares in the last quarter. Seascape Capital Management lifted its position in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after buying an additional 174 shares during the period. Cooper Financial Group boosted its stake in Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company’s stock valued at $479,000 after buying an additional 175 shares in the last quarter. Finally, Martin Capital Advisors LLP grew its position in Edwards Lifesciences by 0.7% in the third quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock valued at $1,686,000 after acquiring an additional 186 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $68.99 on Thursday. The firm has a 50 day moving average of $72.20 and a 200-day moving average of $70.87. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $40.69 billion, a PE ratio of 9.96, a PEG ratio of 3.59 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company’s revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 earnings per share. On average, equities research analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity

In other news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,000 shares of company stock worth $2,195,180. Insiders own 1.29% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the topic of several recent analyst reports. Royal Bank of Canada boosted their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Barclays boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $78.48.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.